Biopharma Daily Stock Updates - 12/23/20

$XBI $151.14 (+0.005%) 📈

COVID:

$BNTX (-0.5%) - Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine

https://biontechse.gcs-web.com/news-releases/news-release-details/pfizer-and-biontech-supply-us-100-million-additional-doses-covid

$MRNA (+3.5%) - Health Canada Authorizes Moderna COVID-19 Vaccine in Canada

https://investors.modernatx.com/news-releases/news-release-details/health-canada-authorizes-moderna-covid-19-vaccine-canada

$SRNE (+18.5%) - Sorrento Announces It Has Submitted An Emergency Use Authorization (EUA) Application to the FDA for COVI-STIX™ Rapid Test for the Detection of SARS-CoV-2 Viral Antigen

https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-it-has-submitted-emergency-use-0

PIPELINE:

$UROV (+0%) - Approval of Gemtesa

https://ir.urovant.com/news-releases/news-release-details/urovant-sciences-announces-us-fda-approval-gemtesar-vibegron-75

$CYTK (+3%) - Cytokinetics Regains European Rights to Omecamtiv Mecarbil

https://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-regains-european-rights-omecamtiv-mecarbil

$SUPN (+14.6%) - Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD

https://ir.supernus.com/news-releases/news-release-details/supernus-announces-positive-results-phase-iii-study-spn-812-0

$TARS (-2.6%) - Tarsus Pharmaceuticals, Inc. Announces Type C Meeting with FDA Regarding NDA Submission Requirements for Lead Candidate TP-03

https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-pharmaceuticals-inc-announces-type-c-meeting-fda